TERT and thyroid cancer, nonmedullary, 2: When the patients were stratified according to the WHO 2017 classification system and TERT promoter mutational status, the HRs of CSS were found to be higher in the EA-FTC patients with M-TERT (HR: 59.09; 95% CI: 5.72–610.68), and the WI-FTC patients with M-TERT (HR 23.26; 2.33–231.78), whereas there were no MI-FTC patients with M-TERT who died of FTC.